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Abstract 
Review of neurochemical investigations in autistic disorder revealed that a wide array of transmitter systems 
have been studied, including serotonin, dopamine, norepinephrine, acetylcholine, oxytocin, endogenous 
opioids, cortisol, glutamate, and gamma-aminobutyric acid (GABA). These studies have been complicated 
by the fact that autism is a very heterogeneous disorder which often presents with comorbid behavioral 
problems. In addition, many of these studies employed very small samples and inappropriate control groups, 
making it difficult to draw conclusions with confidence. Overall, serotonin appears to have the most empirical 
evidence for a role in autism, but this requires further investigation and replication. There is little support for 
the notion that a dysfunction of norepinephrine or the endogenous opioids are related to autism. The role of 
dopaminergic functioning has not been compelling thus far, though conflicting findings on central dopamine 
turnover require further study. Promising new areas of study may include possible dysfunction of the 
cholinergic system, oxytocin, and amino acid neurotransmitters. Implications for pharmacotherapy are 
briefly discussed for each neurotransmitter system with brief research examples. Review of this work 
emphasizes the need for future studies to control for subject variables, such as race, sex, pubertal status, and 
distress associated with blood draws, which can affect measures of neurochemical function. In addition, 
research in neurochemistry must continue to work in concert with other subspecialties to form a more 
comprehensive and theory-based approach to the neurobiological correlates of autistic disorder. 
1. Neurochemical correlates of autistic disorder 
Autism is a pervasive developmental disorder characterized by impaired social interaction, 
deficits in verbal and nonverbal communication, and stereotyped interests and behaviors. Although 
the estimated prevalence in the general population ranges from 0.04 to 0.2% (Sponheim & Skjeldal, 
1998; Chakrabarti & Fombonne, 2001), its emergence early in life, its profound impact on families, 
and its chronic course have resulted in enormous emotional and financial costs (Bristol et al., 
1996). It is now widely accepted that autism is a neurobiological disorder, though specific 
biological markers have yet to be found. However, there are aspects of the disorder which may 
guide future investigations into its pathophysiology. First, this is a developmental syndrome that is 
always observed before 3 years of age. Some families have even reported abnormalities in social 
interests within the first few months of life (Lord, 1995). Therefore, relevant neurochemical or 
neuroanatomical events may occur relatively early in the development of the central nervous 
system (CNS). Affected individuals also exhibit a range of cognitive deficits, with approximately 
75% functioning within the range of mental retardation (Gillberg & Coleman, 1992). In addition, a 
substantial proportion (up to 50%) of patients with autism have abnormal EEGs (Trottier, 
Srivastava, & Walker, 1999), further suggesting underlying brain dysfunction. As is the case with 
many neurodevelopmental syndromes, boys are affected about four times more often than girls 
(Gillberg & Coleman, 1992). There is now strong evidence that autism has a genetic component. 
Siblings of individuals with autism have a prevalence of 2.9 to 3.7%, which represents a nearly 
100-fold increased risk relative to the general population (Bolton et al., 1994; Jorde et al., 1990; 
Szatmari & Jones, 1991). Twin studies have found concordance among monozygotic twins to range 
between 36 and 91%, whereas concordance in dizygotic twins was 1% (Bailey et al., 1995; 
Steffenberg et al., 1989). It is not clear why Bailey et al. and Steffenberg et al. found rates less than 
1% for dizygotic twins whereas Bolton et al., Jorde et al., and Szatmari and Jones found rates of 2.9–
3.7% among siblings. However, these findings all stress the importance of neurobiological 
investigation with regard to the development and expression of autistic disorder. 
Although there is general agreement on the clinical features which define autism, aspects 
of the disorder’s presentation pose obstacles for scientific study. First, there is a tremendous range 
of syndrome expression across individuals according to age or developmental level (Volkmar, 
2001). This heterogeneity of syndrome expression can create difficulties in accurately diagnosing 
autism, particularly among the youngest and lowest-functioning individuals (Lord, 1995; Volkmar 
& Lord, 1998). In particular, some children may exhibit the characteristic impaired social interest 
in the first few years of life but may not exhibit the unusual stereotyped behaviors and resistance to 
change until the following year or two (Lord, 1995). These same issues of symptom emergence are 
also found when attempting to diagnose profoundly retarded individuals, whose limited functional 
level makes detection of some of the features of autism difficult. 
Another obstacle to the study of autism involves the comorbidity of individuals with autism 
(Volkmar & Lord, 1998). Often, people with autism not only present with the classic features of the 
disorder, but also with associated behavioral problems such as hyperactivity, attentional difficulties, 
perseveration, self-injury, and aggression. Currently, there is a tension between the two official 
diagnostic systems; the Diagnostic and Statistical Manual of Mental Disorders (4th ed. [DSM-IV]; 
American Psychiatric Association, 1994), which tends to focus on symptoms, as opposed to the 
International Classification of Diseases-10th edition (World Health Organization, 1994), which 
tends to focus on the single, all-encompassing syndrome (Angold, Costello, & Erkanli, 1999). 
These issues become particularly relevant when working with higher-functioning individuals with 
autism, in whom features of many different psychiatric conditions may be exhibited (Volkmar, 
2001). Whether or not associated behavioral difficulties should be considered part of the syndrome 
of autism complicates an already clinically complex diagnostic issue. 
This diagnostic uncertainty created by developmental level and comorbidity can pose 
considerable problems when trying to delineate the neurochemical features that comprise autistic 
disorder. Of course, the main goal of neurobiological research has been to reveal an 
all-encompassing etiology of autism that could account for the social, cognitive, and 
communication deficits that define the disorder. However, given the range of syndrome expression 
found within the diagnosis, it is hoped that certain biological measures may also have future 
diagnostic or prognostic utility. 
This review seeks to investigate the current findings with regard to the neurochemical 
correlates of autism. While research has also examined other neurobiological aspects of the disorder 
(e.g., neuroanatomical), this article will be restricted to the chemical investigations in persons with 
autism. Neurochemical investigations of other neurobiological disorders (e.g., Parkinson’s disease, 
schizophrenia) have helped to shape etiological theories and guide future pharmacologic 
interventions. In some cases, research in neurochemistry has completely elucidated the cause of 
neurological disorders, as is the case with phenylketonuria (PKU). In this condition, the devastating 
course of the disorder can be largely avoided by keeping phenylalanine out of the diet. 
To date, neurochemical investigation has been most influenced by observed clinical 
responses to pharmacologic treatments; for example, the ‘‘dopamine hypothesis’’ of 
schizophrenia emerged from the significant improvements observed in schizophrenic patients who 
were receiving dopamine-blocking agents. Comparatively, research in the neurochemistry of 
autism has been somewhat less successful thus far, as there have been no known agents that can help 
to treat the core features of the disorder. Investigation into a wide array of chemical systems, 
including the monoamines, various neuropeptides, stress hormones, and amino acid 
neurotransmitters have been conducted, often with conflicting results. This review summarizes 
these investigations, and attempts to point out some of the more promising areas for future research. 
2. Serotonin 
Among all neurochemical investigations in autism, serotonin (5-hydroxytrypamine or 
5-HT) has stimulated the most research and investigation. Serotonin is an indolamine that is derived 
from the essential amino acid tryptophan. Tryptophan is hydroxylated by tryptophan hydroxylase 
to create 5-hydroxytryptophan (5-HTP); this is the rate-limiting step in the synthesis of serotonin. 
Under normal physiological conditions, this enzyme is not fully saturated; therefore, increases in 
dietary tryptophan will usually result in increased levels of serotonin (Marsden, 1981). After 
tryptophan is converted into 5-HTP, it is finally decarboxylated (by 5-HTP decarboxylase) into 
serotonin. 
Centrally, the cell bodies of serotonergic neurons are found in nine clusters, most of which 
are located in the raphe nuclei of the midbrain, pons, and medulla (Carlson, 2001). The two most 
important clusters with regard to behavior are found in the dorsal and medial raphe nuclei, both of 
which send projections to the cerebral cortex (Carlson, 2001; Marsden, 1981). The dorsal raphe 
nucleus also sends neuronal projections to the basal ganglia, an area of the brain important for the 
regulation of motor performance. The median raphe nucleus innervates the dentate gyrus, a part of 
the hippocampal formation (which is implicated in the storage of memory) (Carlson, 2001). 
The behavioral effects of serotonin (5-HT) are complex. It regulates mood, eating, body 
temperature, and arousal, and it modulates pain sensitivity, sexual behavior, and hormone release. 
Initially, interest in 5-HT in autism arose from a consideration of its role in perception (Bauman & 
Kemper, 1994). The powerful effects of serotonergic hallucinogens, such as lysergic acid 
diethyamide (LSD), provided the impetus for early studies of 5-HT in autism. Further evidence for a 
role of serotonin in the expression of autistic disorder was provided by the finding that acute 
depletion of dietary tryptophan (the dietary precursor of serotonin) led to worsening of autistic 
symptomatology (McDougle, Naylor, Cohen, Aghajanian, et al., 1996a; McDougle, Naylor, 
Cohen, Volkmar, et al., 1996b). 
More recently, serotonin’s role in early neural development has also been investigated as a 
possible etiological factor in the development of autistic disorder (Whitaker-Azimitia, 2001). 
Before assuming its role as a neurotransmitter in a mature brain, serotonin regulates both the 
development of serotonergic neurons as well as the development of target tissues, such as the 
hippocampus and the cerebral cortex. Whitaker-Azimitia (2001) suggested that high levels of 
serotonin during early development may cause a loss of serotonin terminals and subsequent 
neuronal development. Interestingly, researchers have shown that higher rates of autistic disorder 
occur in children who were exposed in utero to drugs known to increase serotonin levels, including 
cocaine (Davis et al., 1992; Kramer, Azmita, & Whitaker-Azmita, 1994) and possibly alcohol 
(Nanson, 1992). 
These findings have provided the impetus for investigation of serotonergic abnormalities 
in autistic disorder. Research has examined serotonergic functioning in the blood, cerebrospinal 
fluid, and, more recently, through the use of PET scans and genetic techniques. 
2.1. Blood 5-HT 
Early studies of blood serotonin in autism consistently found hyperserotonemia in one-third 
of people with autism; this has been replicated in more than 25 published studies (e.g., Shain & 
Freedman, 1961; Ritvo et al., 1970; Campbell et al., 1975; Takahashi, Kanai, & Miyamoto, 1976; 
McBride et al., 1998). The magnitude of this elevation is usually expressed as 5-HT in whole 
blood, and has typically been about 50% above normal levels (McBride et al., 1998). Subsequent 
research has established that more than 99% of whole blood serotonin is contained in the platelets 
(Anderson et al., 1987) and that platelet serotonin accounts for the hyperserotonemia in autism 
(Cook, Leventhal, & Freedman, 1988). 
Animal research has indicated that hyperserotonemia can reduce the drive for social 
attachment by inhibiting separation distress (Chamberlain & Herman, 1990); this could perhaps 
account for the deficits in social relatedness found in individuals with autism. However, the cause 
and significance of these elevated levels of blood serotonin in autism remain unclear. One might 
assume that hyperserotonemia, because it is an abnormal finding, would serve as a marker for 
impairment or dysfunction. However, two studies have failed to show the expected inverse 
relationship between blood 5-HT and verbal expressive ability (Cook et al., 1990; Cuccaro, Wright, 
Abramson, Marsteller, & Valentine, 1993) in individuals with autism, so it is unknown how 
hyperserotonemia could play a role in autism’s expression. 
In addition, it is difficult to draw conclusions about what these peripheral measurements 
tell us about the central differences in autism; nearly all of the 5-HT found in the blood is 
manufactured in the gut prior to absorption by platelets. Hyperserotonemia is not found 
exclusively in autism; it is also found in a variety of medical and neuropsychiatric disorders such 
as schizophrenia (Freedman, Belendiuk, Belendiuk, & Crayton, 1981), Huntington’s disease 
(Belendiuk, Belendiuk, & Freedman, 1980), and severe mental retardation (Hanley, Stahl, & 
Freedman, 1977; Pare, Sandler, & Stacey, 1960; Partington, Tu, & Wong, 1973). It is notable that 
the children first reported as having elevated blood serotonin in Shain and Freedman’s (1961) 
landmark paper were diagnosed not only with autistic disorder, but with severe mental retardation 
as well. It is likely that most reports of blood 5-HT are complicated by factors beyond the 
diagnosis of autistic disorder. 
In an attempt to elucidate some of these variables, McBride et al. (1998) examined the 
effects of diagnosis (autistic versus mentally retarded versus typically developing), race, and 
puberty on blood levels of serotonin. They found among prepubertal children only, significant 
effects of diagnosis (with subjects with autism having higher 5-HT levels) and race (with white 
children having lower 5-HT levels than black or Latino youngsters, regardless of diagnosis). 
While these findings confirm that hyperserotonemia is more prevalent in children with autism, 
McBride et al. also stressed the importance of matching for pubertal status and race when 
conducting neurochemical research. It is possible that the hyperserotonemia reported in individuals 
with autism may have been overestimated due to failure to control for subject variables (McBride et 
al., 1998). Clearly, the study of whole blood serotonin is a complex issue; it is present in a variety 
of neurological disturbances, and it yields very little information about central serotonergic 
functioning. Therefore, it alone may not shed any light on the specific etiological mechanisms that 
are exclusive to autistic disorder. 
2.2. CSF 5-HIAA 
To assess central serotonergic functioning in autism, seven studies examined levels of 
5-hydroxyindoleacetic acid (5-HIAA; serotonin’s major metabolite) in cerebral spinal fluid (CSF). 
Because nearly all 5-HT in the brain is metabolized to 5-HIAA before elimination, measurement of 
5-HIAA in CSF provides a relatively accurate measure of central levels of serotonin, as it has been 
shown that it is not contaminated with 5-HT or 5-HIAA that is found elsewhere in the body 
(Anderson & Hoshino, 1997). The seven studies (Cohen, Shaywitz, Johnson, & Bowers, 1974; 
Cohen, Caparulo, Shaywitz, & Bowers, 1977; Winsberg, Sverd, Castells, Hurwic, & Perel, 1980; 
Gillberg, Svennerholm, & Hamilton-Helberg, 1983; Ross, Klykylo, & Anderson, 1985; Narayan, 
Srinath, Anderson, & Meundi, 1992) we were able to locate are summarized in Table 1. 
Researchers have theorized that central serotonergic functioning is depressed in 
individuals with autism, as supported by the efficacy of serotonin reuptake inhibitors (SSRIs) in 
treating rituals and aggression in autism, at least in adults with autism (Cook, Rowlett, Jaselskis, & 
Leventhal, 1992; Gordon, State, Nelson, Hamburger, & Rapoport, 1993; McDougle et al., 
1996a,b), as well as the finding that acute tryptophan depletion caused worsening of autistic 
symptomatology (McDougle et al., 1996a,b). However, the seven reports of measurements of 
5-HIAA in CSF were consistent in showing no differences between autistic and control groups. 
These findings suggest that if there is a central serotonergic abnormality in autism, it does not 
involve a widespread or marked change in the turnover of 5-HT (Anderson, 1994). 
2.3. Positron emission tomography (PET) studies 
Recently, α-[11C]methyl-L-tryptophan ([11C]AMT) has been developed as a tracer for 
measuring serotonin synthesis in the brain, using positron emission tomography (PET). PET 
allows one to observe the regional variance in serotonin synthesis and thus is a much more precise 
and informative measure of central serotonergic functioning in autism. To date, there have been 
two published studies using this method in subjects with autism. The first, conducted by Chugani et 
al. (1997) measured 5-HT synthesis in eight children with autism (seven boys, one girl: mean age 
6.6 years) and five of their siblings (four boys, one girl; mean age 9.9 years). A diagnosis of autism 
was made using DSM-IV criteria, as well as meeting the criteria for autism using the Gilliam 
Autism Rating Scale (GARS) and the Childhood Autism Rating Scale (CARS). 
Examination of the PET images revealed clear differences between the boys with autism and 
their siblings. In boys with autism, unilateral decreased 5-HT synthesis was found in the frontal 
cortex and thalamus and increased levels were found in the contralateral dentate nucleus of the 
cerebellum. For five of the seven boys, decreased accumulation was seen in the left frontal cortex 
and thalamus, accompanied by elevated accumulation on the right dentate nucleus. The remaining 
two boys had the mirror opposite image pattern of abnormality, with decreased accumulation seen 
in the right frontal cortex and thalamus with increased accumulation seen on the left dentate 
nucleus. This ‘‘reversed’’ pattern was not related to handedness or any other obvious subject 
characteristic. The frontal cortex, thalamus, and dentate nucleus are all connected via the 
dentatothalamocortical pathway, which is involved in sensory integration and speech 
production—skills that are significantly impaired in individuals with autistic disorder. In addition, 
the finding that 5-HT synthesis is elevated in one area and lowered in another could explain why 
measurements of 5-HIAA in CSF (discussed previously) have not shown any overall mean 
differences, as these differences in regional serotonin synthesis could in essence cancel one another 
out (Chugani et al., 1997). 
A subsequent study by Chugani et al. (1999) examined the effects of age on serotonin 
synthesis in autistic and typically-developing subjects. This study had a larger sample size, 
 
involving 30 subjects with autism (24 boys, 6 girls, age range of 2.3–15.4 years), 8 of their siblings 
(6 boys, 2 girls, age range of 2.1–14.4 years), and 16 children with epilepsy (9 boys, 7 girls, age 
range 3 months to 13.4 years). A diagnosis of autism was rigorously fulfilled using DSM-IV 
criteria, as well as meeting criteria from the GARS, CARS, and the Autism Diagnostic 
Interview—Revised (ADI-R; Lord, Rutter, & Le Couteur, 1994). Examination of the PET images 
revealed that children without autism between the ages of 2 and 5 years showed high levels of 5-HT 
synthesis, which subsequently declined towards adult values between the ages of 5 and 14 years. 
Children with autism, on the other hand, did not show this decline in serotonin synthesis capacity 
over time; in fact, levels were significantly lower in these children at age 2–5 compared to controls 
and increased slightly with age (observed in both male and female subjects). This suggests that 
developmental regulation of serotonin synthesis may be involved in the pathogenesis of autism. As 
in the previous study, focal abnormalities were noted in boys with autism regardless of age, with 
increased serotonin synthesis seen in the frontal cortex and thalamus. The subjects with epilepsy 
also showed focal regions of increased 5-HT synthesis that were associated with the foci of their 
epilepsy. Focal differences were not observed in girls with autism, which could be due in part to 
gender differences in hemispheric specialization, but this requires further study. 
2.4. Genetic studies 
Motivated by the evidence for a genetic basis of autism (as evidenced by sibling and twin 
studies), researchers have begun to investigate potential candidate genes for the development and 
expression of autism. Some of this research has focused on the serotonin transporter gene (SLC6A4), 
which encodes for both the platelet and neuronal transport of 5-HT. Interest in this gene can be 
attributed to its possible role in the platelet hyperserotonemia in autism and to the clinical utility of 
SSRIs (which target these transporter proteins). 
Two polymorphisms have been reported for SLC6A4: the deletion or short (s) allele and the 
long (l) alelle (Tordjman et al., 2001). These polymorphisms are functionally significant; cell lines 
with sl or ss genotypes are shown to have approximately one-half the rates of 5-HT transport when 
compared to cell lines with ll genotypes (Lesch, Wolozin, Murphy, & Riederer, 1993). 
Theoretically, an ‘‘overactive’’ serotonin transporter (e.g., one with a ll genotype) would take 5-HT 
out of the synaptic cleft too quickly, causing a relative deficiency. This would be in line with the idea 
that areas of central serotonergic functioning are depressed in individuals with autism. 
We located six studies examining polymorphisms of this gene in autism (Cook et al., 1997; 
Klauck, Poutska, Benner, Lesch, & Poutska, 1997; Maestrini et al., 1999; Persico et al., 2000; 
Tordjman et al., 2001; Yirmiya et al., 2001), and these are summarized in Table 2. Results do not 
provide clear evidence for consistent genotypic characteristics of people with autism: three studies 
failed to show any association of either polymorphism to autism, two studies showed preferential 
transmission of the long polymorphism, and one study showed preferential transmission for the 
short polymorphism. 
At this point, it is difficult to determine the role of the serotonin transporter gene in autism. 
It is likely that autism will be characterized by genetic heterogeneity, and as is the 
 
case with many complex conditions, one gene may not be necessary or sufficient to produce the 
disorder (Yirmiya et al., 2001). Genetic heterogeneity would be consistent with the clinical 
heterogeneity in autism noted earlier. It is then notable that in one of the studies, while failing to 
find that any specific genotype conveyed risk for developing autistic disorder, the investigators 
found that the severity of autism was impacted by genotype, with greater l transmission being 
observed in mild/moderate cases of autism and greater s transmission observed in more severely 
impaired individuals (Tordjman et al., 2001). It is possible that while the serotonin transporter gene 
may not serve as a clear marker for autism, it may influence its behavioral phenotypic expression. 
Clearly, the study of serotonin in autism is a complex issue, and more research is needed in order to 
elucidate its possible role in autistic disorder. 
2.5. Clinical/treatment implications 
These potential abnormalities in serotonergic function naturally lead to hypotheses about 
treatment possibilities, and a number of strategies have been tried. Researchers have conducted 
investigations of L-Dopa and numerous studies of fenfluramine (both lower blood serotonin, 
presumably by relieving serotonergic-deficit up-regulation of serotonin production) in individuals 
with autism in hopes of producing clinical improvement. These studies failed to show consistent 
significant clinical benefit (Aman & Kern, 1989; Campbell, Anderson, & Small, 1990). 
A large number of investigators have shown interest in the selective serotonin reuptake 
inhibitors (SSRIs; e.g., fluoxetine, paroxetine, citalopram) for various reasons. Beyond the 
‘‘serotonin hypothesis’’ discussed above, these agents are also known to be effective as 
antidepressants and as effective anti-OCD (obsessive compulsive disorder) agents. The presence 
of restricted repetitive behavior in individuals with autism may justify the use of these medications 
for some practitioners. In fact, recent surveys of medication use in autism have reported that SSRIs 
are the most commonly-prescribed psychotropic medication in autism (Langworthy-Lam, Aman, 
& Van Bourgondien, 2002; Aman, Lam, & Collier-Crespin, 2003). Aman, Arnold, and Armstrong 
(1999) reviewed 47 case reports and studies of SSRIs and clomipramine, a serotonergic tricyclic 
antidepressant, in subjects with developmental disabilities (including autism). A large 
majority—but not all—of these reports suggested that these agents were often effective in 
managing perseverative behavior, including compulsions, stereotypies, and self injury (Aman et 
al., 1999). Further controlled research is needed, especially in pediatric samples, as it is possible 
that SSRIs may have different effects in younger people with autism. These differential effects 
may be related to the developmental variations in serotonin levels described above. 
The atypical antipsychotics can be characterized as dopamine and serotonin receptor 
blockers. Although discussion of antipsychotics belongs more properly in the next major section, 
they deserve brief mention here. Recently, the Research Units on Pediatric Psychopharmacology 
(RUPP) Autism Network (2002) assessed risperidone in a double blind, placebo controlled trial in 
101 children chosen for high levels of irritability. Risperidone had a variety of therapeutic effects 
on both comorbid irritable behaviors and stereotypic/compulsive behavior. 
3. Dopamine 
Dopamine (DA) is a catecholamine that is synthesized from the dietary amino acid 
tyrosine. Once ingested, tyrosine is hydroxylated (by tyrosine hydroxylase) into 
L-dihydroxyphenylalanine (L-DOPA). This is the rate-limiting step of the synthesis of dopamine. 
L-DOPA is then converted to dopamine via the enzyme DOPA decarboxylase. Most DA-containing 
neurons lie in the midbrain; in particular, three important DA systems project from the substantia 
nigra and the ventral tegmental area (Carlson, 2001). The nigrostriatal system has cell bodies 
located in the substantia nigra that project their axons to the neostriatum, an area that is involved in 
the control of movement. The mesolimbic system contains cell bodies in the ventral tegmental area 
and projects axons to several parts of the limbic system, including the nucleus accumbens (which 
plays a role in the reinforcing effects of certain stimuli), the amygdala (involved in emotion) and 
the hippocampus (involved in memory). Lastly, the mesocortical system also has its cell bodies in the 
ventral tegmental area; its axons, however, project to the prefrontal cortex, an area critical for 
higher-order functions, such as planning and formation of short-term memories (Carlson, 2001). 
In general, the dopaminergic system is thought to affect a wide range of behaviors and 
functions, including cognition, motor function, brain-stimulation reward mechanisms, eating and 
drinking behaviors, sexual behavior, neuroendocrine regulation, and selective attention (Calne, 
Chase, & Barbeau, 1975; Costa & Gessa, 1977; Roberts, Woodruff, & Iversen, 1978). Interest in 
the role of DA in autism began with the observation that some DA blockers (i.e., antipsychotics) 
have been observed to be effective in treating some aspects of autism (Anderson & Hoshino, 1997). 
Specifically, the antipsychotics appear to alleviate hyperactivity, stereotypies, aggression, and 
self-injury (Young, Kavanagh, Anderson, Shaywitz, & Cohen, 1982). In addition, animal research 
has shown that stereotypies and hyperactivity can be induced by increasing dopaminergic 
functioning. These observations suggested that dopaminergic neurons could be overactive in 
autism, which led to studies of DA function. These were done by several methods, including blood 
and urine measurements of DA and its major metabolite, and measurements of this metabolite in 
CSF. 
3.1. Blood and urine 
Once released from the neuron, central DA is broken down into homovanillic acid (HVA) 
and 3,4-dihydroxyphenylacetic acid (DOPAC). These substances, as well as DA itself, can be 
measured in both blood and urine. Measurements of urinary excretion of DA and HVA in autism 
have been essentially equivocal. Although some researchers have reported increased levels in 
autism (see Anderson & Hoshino, 1997 for a review), in a large study of autistic versus control 
subjects, no differences were found (Minderaa et al., 1989). In the one study that examined plasma 
levels of DA metabolite, no differences between autistic and control subjects were found 
(Minderaa et al., 1989). At this point, there does not appear to be any evidence of peripheral 
dopaminergic abnormalities of autism; in addition, it is not clear how these peripheral 
measurements relate to central dopaminergic functioning (Anderson & Hoshino, 1997). It has been 
suggested that only about 25% of blood or urine HVA is of central origin (Elchiasak, Polinsky, 
Ebert, Powers, & Kopin, 1978; Maas, Hattox, Greene, & Landis, 1980). Therefore, these 
measurements would only be capable of detecting widespread or marked alterations in the 
metabolism of DA in the brain (Anderson, 1994). 
3.2. CSF HVA 
In order to assess central dopaminergic functioning, measures of CSF HVA have been 
conducted. A total of seven studies in individuals with autism were located (Cohen et al., 1974, 
1977; Winsberg et al., 1980; Gillberg et al., 1983; Gillberg & Svennerholm, 1987; Ross et al., 
1985; Narayan et al., 1992) and are described in Table 3. In two of these studies (Gillberg et al., 1983; 
Gillberg & Svennerholm, 1987) approximately 50% of subjects with autism exhibited significantly 
elevated levels of CSF HVA. The remaining five studies showed no significant mean differences 
between control subjects and subjects with autism. 
However, in the Cohen et al. studies (1974, 1977), though no significant group differences 
were found, the children with autism who displayed greater hyperkinesis and more severe 
stereotypies tended to have higher CSF HVA levels. These findings are similar to those found in 
studies examining symptom severity in Tourette’s disorder, where higher CSF HVA levels were 
correlated with more severe tics (Cohen et al., 1978). In addition, it has been found that CSF HVA 
levels are generally higher in males than in females (Leckman et al., 1980). Perhaps the higher CSF 
HVA levels in autism could be due in part to the markedly higher prevalence of the disorder in 
males (Young et al., 1982). At this point, whether or not central DA turnover is increased in autism 
is still a subject of debate (Gillberg, 1993; Narayan et al., 1992). These studies do not provide 
strong support for increased CSF HVA levels in autism. Taken together with the blood and urine 
studies, there is little evidence for differences between autistic and control subjects in 
neurochemical indexes in DA functioning. 
3.3. Clinical/treatment implications 
The more positive findings above led to early trials of dopamine-blocking agents, notably 
classical antipsychotic drugs, as possible treatment for core autistic symptoms. Some success has 
been demonstrated for repetitive, stereotyped behaviors, which, of all autistic symptoms, seem 
most closely linked theoretically with excess dopamine transmission (Schroeder, 1988; Ernst et al., 
1999). Hyperactivity and aggression also were sometimes improved. 
In the RUPP Autism Network (2002) study mentioned previously, treatment with 
risperidone caused reductions on all subscales of the Aberrant Behavior Checklist (Aman & Singh, 
1994), with large reductions occurring on the Irritability, Stereotypic Behavior, and Hyperactivity 
subscales. Smaller, marginally-significant, effects were also observed on the Lethargy/Social 
Withdrawal and Inappropriate Speech (often manifested as echolalia) subscales. It is not clear 
whether risperidone truly influenced core symptoms or whether the changes seen in these core 
manifestations were a ‘‘halo’’ effect of major symptom reduction in acting out symptoms. 
McDougle et al. (in press) reported on other (‘‘secondary’’) measures from the RUPP study. They 
reported significant drug-related 
 
improvements in restricted, repetitive, and stereotyped patterns of behavior but not in social 
interactions and communication. At this stage, it is not clear whether longer exposure to 
risperidone or other atypical antipsychotics may produce lasting changes in core manifestations of 
autism. 
4. Norepinephrine 
Norepinephrine (also known as noradrenaline) is a catecholamine that is synthesized from 
DA through the action of the enzyme DA beta-hydroxylase. Nearly every region of the brain 
receives input from noradrenergic neurons (Carlson, 2001). The cell bodies of the most important 
system are located in the locus coeruleus, which is located in the dorsal pons. The projections of 
this area are distributed widely throughout the brain, and activity of these systems is thought to play 
a critical role in attention, filtering of irrelevant stimuli, stress response (e.g., ‘‘fight or flight’’ 
response), anxiety, and memory (Amaral & Sinnamon, 1977; Moore & Bloom, 1979). Since many 
of these functions are impaired in individuals with autism, researchers have investigated whether 
noradrenergic functioning within the diagnosis is altered. Noradrenergic activity has been assessed 
in autism via measurement of norepinephrine (NE) and its central and/or peripheral metabolites in 
blood, urine, and CSF. 
4.1. Blood studies 
Noradrenergic function can be measured in the blood as NE itself, and as its principal 
central metabolite, 3-methoxy-4-hydroxyphenylglycol (MHPG). Unlike some of the other 
neurotransmitter systems, central and peripheral noradrenergic systems are tightly coupled 
(Schildkraut et al., 1978) with blood and CSF concentrations being highly correlated (Raskind, 
Peskind, Halter, & Jimerson, 1984; Roy, Pickar, DeJong, Karoum, & Linnoila, 1988; Ziegler, 
Wood, Lake, & Kopin, 1977). As a result, peripheral measurements may give a good perspective 
on central noradrenergic functioning. A total of seven studies examining NE system levels in the 
blood were located; these are listed in Table 4. Five of these, all of which measured NE, showed 
higher concentrations in subjects with autism as compared with controls (Lake, Ziegler, & 
Murphy, 1977; Launay et al., 1987; Cook et al., 1990; Leventhal, Cook, Morford, Raviatz, & 
Freedman, 1990; Leboyer, Bouvard, & Launay, 1992). The results of the remaining two studies, 
which measured MHPG levels, failed to show any differences between individuals with autism 
and normal controls (Young et al., 1981; Minderaa, Anderson, Volkmar, Akkerhuis, & Cohen, 
1994). 
4.2. Urine studies 
Studies examining excretion of NE and its metabolites in individuals with autism have 
yielded inconsistent findings. When analyzing excretion rates of norepinephrine, researchers have 
found increased (Barthelemy et al., 1988), decreased (Young, Cohen, Brown, & Caparulo, 1978), 
as well as equivocal (Launay et al., 1987; Martineau, 
 
Authors Subjects Medication free? Criteria for 
diagnosis of 
autism 
Main findings 
Plasma Norepinephrine  
Lake et al (1977). 11 autistic children, mean 
age 15 years (S.D. = 2.0); 
12 typically-developing 
controls, matched for age, 
mean age 15 years (S.D. = 
1.0) 
No Kanner’s 
Criteria 
↑ In autistic 
subjects 
Launay et al. 22 autistic children, mean 
age 10.5; 22 typically 
developing controls, 
matched for age and sex 
Two subjects on meds: 
thioridazine and 
pericytazine, tested in 
vitro to have no effect on 
NE 
DSM III ↑ In autistic 
subjects (1987)  
Cook et al. 16 autistic children; 21 
siblings of autistic 
children; 53 parents of 
autistic children 
Not known DSM III ↑ In autistic 
subjects, 
especially in 
those with 
hyperserotonemi
(1990)   
Leventhal et al. 39 autistic children, mean 
age 8.99 (S.D. = 4.4); 32 
siblings of autistic 
children, mean age 11.2 
years (S.D. = 5.3); 78 
parents of autistic children, 
mean age 38.7 years (S.D. 
= 6.5); 98 unrelated adult 
controls, mean age 28.2 
(S.D. = 8.4) 
Yes DSM III ↑ In autistic 
subjects (1990)   
Leboyer et al. All subjects autistic with 
severe MR and SIB: 1 
autistic female, aged 12 
years; 3 autistic males, 
aged 4 years, 12 years, and 
19 years 
One subject on a 
neuroleptic 
DSM III ↑ In autistic 
subjects 
(1992)  
Plasma MHPGa     
Young et al. (1981) 10 autistic subjects, mean 
age 10.6 years (S.D. = 4.5); 
15 subjects with Tourette’s 
syndrome, mean age 16.1 
(S.D. = 11.1); 8 typically 
developing boys, mean age 
11.9 years (S.D. = 10.6) 
No DSM III No difference 
Minderaa et al. 40 autistic individuals, 
mean age 20.0 years (S.D. 
= 4.4); 20 age- and 
sex-matched typically 
developing controls, mean 
age 19.6 years (S.D. = 6.7)
No, but grouped 
according to drug use; no 
effect 
DSM III No difference
(1994)   
↑ Significantly higher. 
a MHPG = 3-methoxy-4-hydroxyphenylglycol (principal central metabolite of norepinephrine). 
Table 4. Studies examining noradrenergic functioning 
Barthelemy, Jouve, Muh, & Lelord, 1992; Minderaa et al., 1994; Croonenberghs et al., 2000) 
concentrations in individuals with autism when compared to control subjects. Other studies looking 
at excretion rates of MHPG have reported decreased (Young et al., 1978; Barthelemy et al., 1988) 
and normal (Launay et al., 1987; Minderaa et al., 1994) activity in subjects with autism. Lastly, 
studies examining levels of norepinephrine’s predominant peripheral metabolite, vanillylmandelic 
acid (VMA) did not produce significant differences between autistic and control subjects 
(Minderaa et al., 1994). 
4.3. Studies of CSF 
Two studies measuring levels of MHPG in cerebrospinal fluid were located (Young et al., 
1981; Gillberg & Svennerholm, 1987). Both of these studies used DSM-III criteria to diagnose 
autism, and neither study showed any significant difference between autistic and control subjects. 
Overall, these results indicate that the only consistent abnormal finding with regard to 
noradrenergic functioning in autism is elevated plasma norepinephrine levels. All other 
measurements suggest that noradrenergic functioning is not greatly altered within the disorder. 
Initially, the elevated plasma NE may seem to be in conflict with all of these other null findings. 
However, when one considers the time frame of the various measures, these seemingly disparate 
findings may be reconciled. It is known that plasma NE has an extremely short half-life and largely 
reflects the state of sympathetic arousal at the time of blood drawing (Minderaa et al., 1994). The 
other measurements of blood, urine, and CSF are time-averaged indices of noradrenergic 
functioning. It is then possible that baseline NE functioning is normal in subjects with autism, but 
that clinical procedures (such as drawing blood) may lead to hyperarousal and a heightened 
sympathetic response (Minderaa et al., 1994; Cook, 1990), thus resulting in temporarily higher 
levels of NE in the blood. Collectively, these results suggest little role for NE in the expression and 
etiology of autistic disorder. 
4.4. Clinical/treatment implications 
Consistent with the paucity of findings above, benefit from norepinephrine agonists and 
antagonists in autism has been sparsely reported, inconsistent, and clouded with adverse events. 
Tricyclic antidepressants such as imipramine, desipramine, and nortriptyline are all norepinephrine 
reuptake blockers, although they have other actions, such as dopamine presynaptic reuptake 
blockade. Gordon et al. (1993) compared placebo, desipramine, and clomipramine in 24 subjects 
with autistic disorder. Both desipramine and clomipramine reduced hyperactivity, whereas 
clomipramine had additional effects on stereotypic, compulsive, and ritualistic behavior. Thus the 
adrenergic effect seemed to be confined to hyperactivity, whereas clomipramine’s effect on 
perseverative behavior appears to be due to its serotonergic effects (discussed previously in the 
serotonin section). McDougle and Posey (2003) noted that alpha 2 agonists like clonidine and 
quanfacine, which dampen noradrenalin action, are sometimes helpful for managing hyperactivity 
in young people with autism. However, the drugs do not appear to affect any of the core 
manifestations of autism. Postsynaptic beta blockers, like propranolol and nadolol, are sometimes 
helpful for managing aggression, self injury, and agitation (Fraser, Ruedrich, Kerr, & Levitas, 
1998), but again they appear to have no consistent effect on manifestations of autism. 
5. Acetylcholine 
Acetylcholine (ACh) is the neurotransmitter found at the neuromuscular junction, in 
autonomic nervous system ganglia, and in multiple sites in the CNS (Kandel, Schwartz, & Jessel, 
1995). In the brain, three systems have been of interest to neuroscientists: the dorsolateral pons 
(involved in REM sleep), the basal forebrain (which activates areas of the cerebral cortex and 
facilitates learning), and the medial septum (which projects to the hippocampus, an area involved 
in memory). There are two kinds of ACh receptors: nicotinic and muscarinic. Both are found in the 
brain, though muscarinic receptors are more prevalent. Overall, the cholinergic system has been 
referred to as an ‘‘action system’’ that helps develop the ability to focus on the environment and 
achieve a coherent behavioral response (Stahl, 1996). 
The role of acetylcholine deficits in autism has not been explored until recently. However, 
a report of neuropathological abnormalities in cholinergic neurons located in the basal forebrain of 
individuals with autism has generated interest in the study of acetylcholine (Bauman & Kemper, 
1994). Since the cholinergic system has been shown to play a role in the development and function 
of cognitive abilities, it has been hypothesized that a disruption in this system could be linked to 
the cognitive deficits that often accompany autism (e.g., problems with attention, learning). At this 
point, investigators have only begun to examine ACh function in autism, via postmortem studies 
of acetylcholine function and medication studies, which are summarized below. 
5.1. Postmortem studies 
A series of three studies examining cholinergic activity in autism postmortem were located 
(Perry et al., 2001; Lee et al., 2002; Martin-Ruiz et al., 2004). In the first of these studies, Perry et 
al. (2001) compared the brains of individuals with autism to the brains of individuals with mental 
retardation, as well as to the brains of typically-developing individuals matched for age. Measures 
of cholinergic enzyme markers (acetylcholinetransferase and acetylcholinesterase) showed no 
significant differences between groups. However, analysis of receptor binding revealed a large 
(65–75%) and significant reduction in ACh binding in nicotinic (alpha 4 and beta 2) receptors in 
the parietal and frontal cortexes in autism. Significant reductions (30%) in muscarinic (M1) 
receptors in the parietal cortex were also found in individuals with autism. Subsequent research 
has assessed further potential abnormalities of nicotinic receptors in autism (Lee et al., 2002; 
Martin-Ruiz et al., 2004). However, it is unclear how these differences might be related to the 
etiology of autism. It has been suggested that the findings of decreased nicotinic receptor function 
may provide a cue for possible medication interventions, as nicotinic receptor agonists are known 
to enhance attentional function (Lee et al., 2002). 
5.2. Clinical/treatment implications 
At this stage, the best strategy for boosting the action of ACh in the brain is to inhibit 
agents that metabolize ACh. Several drugs have been developed to fight the brain-wasting that 
occurs with Alzheimer’s disorder. They work to increase central ACh activity by leaving it in the 
synaptic cleft longer before it is broken down by enzymes. Researchers have begun to investigate 
the use of acetylcholinesterase inhibitors, including donezepil (Chez, Tremb, Nowinski, & 
Field-Chez, 2001; Hardan & Handen, 2002), galantamine (Niederhofer, Staffen, & Mair, 2002), 
and rivastigmine tartate (Chez, Aimonovitch, Buchanan, Mrazek, & Tremb, 2004) in autism. Two 
of these investigations were double-blind, placebo-controlled studies, and both reported 
improvements with active treatment (Niederhofer et al., 2002; Chez et al., 2001). Niederhofer et al. 
reported improvements in irritability, whereas Chez et al. (2001) reported improvements in 
symptoms of autism and in language. Hardan and Handen (2002) treated eight patients having 
autism with donepezil in an open trial. Four of them were regarded as showing substantial 
improvement, with behavioral changes largely occurring in the areas of irritability and 
hyperactivity. These results provide preliminary evidence for the use of acetylcholinesterase 
inhibitors in autism, and they suggest that further study of the cholinergic system in autism is 
warranted. 
6. Oxytocin 
Oxytocin (OT) is a peptide synthesized in the paraventricular nucleus (PVN) and the 
supraoptic nucleus (SON) in the brain. Cells in the PVN that synthesize oxytocin project diffusely 
throughout the brain and the brainstem (Sofroniew & Weindl, 1981). It has also been found that 
receptors for oxytocin are located throughout the limbic system in the forebrain and in the 
autonomic centers in the brainstem (Barberis & Tribollet, 1996). These observations strongly suggest 
that OT acts centrally as a neuromodulator (Insel, O’Brien, & Leckman, 1999). 
Behaviorally, the OT system has been implicated in maternal behavior, infant separation 
distress, sexual behavior, and in the development of social attachments (Insel et al., 1999; Insel, 
1992). Animal research has provided much of the groundwork for these findings; for example, in 
monogamous prairie voles, oxytocin was shown to be both necessary and sufficient for the normal 
development of partner selection in females (Insel & Hulihan, 1995). If an oxytocin antagonist is 
administered to these species, pair bonding will not occur. Conversely, if oxytocin is administered 
centrally, pair bonding is facilitated, even in the absence of mating. 
Given that social impairment is a primary symptom of autistic disorder, researchers have 
begun to investigate whether or not the OT system is dysfunctional in individuals with autism. 
However, research in this area is in its infancy. To date, there has been one study examining blood 
levels of oxytocin (Modahl et al., 1998). A total of 29 boys with autism and 30 controls between 
the ages of 6 and 11 were studied; this involved a blood draw, as well as a series of social and 
developmental measures. As a group, subjects with autism had significantly lower levels of 
oxytocin. Moreover, when the relationships of OT to subject characteristics were examined, two 
interesting trends emerged. 
First, OT plasma levels were positively associated with age for normal children, but not for 
children with autism. The rise in OT in older children is consistent with the surge of other hormone 
systems that increase before the onset of puberty in normal children (Modahl et al., 1998). The lack 
of an increase in OT in children with autism may reflect delay in physical maturation in this group 
(Campbell et al., 1980; Simon & Gillies, 1976) or a failure of the trigger for developmental 
increase in OT. Second, and perhaps more interestingly, in normal children oxytocin levels were 
positively related to socialization skills. However, oxytocin levels were negatively related to 
socialization skills in children with autism (Modahl et al., 1998). This finding suggests that a simple 
OT deficit model in autism is not adequate. Rather, these lower blood oxytocin levels may reflect 
compensatory mechanisms for underlying abnormalities in receptors or substances upstream from 
OT, resulting in secondary dysregulation (Modahl et al., 1998). These studies can be viewed as 
preliminary suggestive evidence that oxytocin dysregulation may play a role in the disorder. 
6.1. Clinical/treatment implications 
The intriguing findings above raise hope of finding some neurochemical treatment that 
might directly address the social impairment of autism, which, in contrast to stereotyped behavior, 
has generally been resistant to psychopharmacology. Recently, data were presented from a study in 
which 15 adults with autism or Asperger’s disorder were infused with either synthetic OT (pitocin) 
or placebo in a double-blind crossover fashion (Hollander et al., 2003). Administration of oxytocin 
resulted in significant decreases in repetitive behaviors in subjects with autism. Social impairment 
was not assessed. More investigation of this hormone would be helpful in determining if it has a 
therapeutic role to play. Unfortunately, synthetic OT (pitocin) is only available in an injectable 
vehicle, which impedes efforts to assess what its effects may be in more real-life settings. 
Furthermore, having administration confined to injections would seriously limit the practical 
utility of most agents with short times of action. 
7. Endogenous opioids 
Endogenous opioids are peptides that exert effects on the central nervous system, acting as 
neuromodulators. There are three distinct types: beta-endorphins, enkephalins, and dynorphin. 
Each type of opioid has a different affinity for a certain receptor subtype: beta-endorphins for mu 
receptors (implicated in analgesia and euphoria), the enkephalins for mu and delta (less understood, 
perhaps associated in analgesia and reinforcement), and dynorphins for kappa receptors 
(implicated in spinal analgesia). 
Opioid peptides appear to be endogenous ligands for the receptors activated by morphine 
and related compounds (Anderson & Hoshino, 1997). Some of the behavioral effects of opiate 
administration include (a) insensitivity to pain, (b) affective lability, (c) stereotyped behaviors, and 
(d) reduced socialization (Kalat, 1978; Panksepp, 1979; Sandman, 1991, 1992). Since these effects 
are consistent with some of the symptoms of autism, researchers have theorized that an increase in 
opioid functioning could play a role in the disorder (e.g., Panksepp, 1979; Anderson, 1994). This 
hypothesis has been tested by assessing opioid levels (beta-endorphin, in particular) in the blood 
and CSF, as well as by the administration of opiate agonists. 
7.1. Blood and CSF studies 
Previous studies examining levels of endogenous opioids in the blood have yielded 
inconsistent results. These studies are summarized in Table 5. Nine studies were located, all of 
which examined levels of beta-endorphin (BE). Four groups of investigators reported elevated 
levels in subjects with autism, while four other groups reported decreased levels when compared to 
control groups. Three studies reported equivocal findings. It is notable that BE in the plasma is 
derived from the pituitary, and does not cross the blood-brain barrier. Therefore, it is not a clear 
indicator of central functioning; rather, elevated levels of BE in the blood appear to reflect acute 
stress (Tordjman et al., 1997; Anderson & Hoshino, 1997). It is then possible that any elevated BE in 
blood could be a result of the stress of the blood draw itself, and therefore, not give a sense of 
baseline BE levels. 
Studies of endogenous opioids in cerebrospinal fluid are less common (see Table 5). Three 
studies were located, one of which indicated elevated levels when compared to controls (Ross, 
Klykylo, & Hitzemann, 1987), one which displayed decreased levels (Gillberg, Hagberg, 
Witt-Engerstom, & Eriksson, 1990) and one which showed levels similar to controls (Nagamitsu, 
1993). It is difficult to draw any conclusions from these studies, especially considering the small 
number of subjects employed and the use of control subjects that may not be representative [e.g., 
using normal adults as a control group for children with autism (Gillberg et al., 1990)]. 
At this point, the study of opioid activity in autism has produced little of clinical relevance 
beyond the symptomatic reduction of self-injury and hyperactivity in some subjects. 
7.2. Clinical/treatment implications 
A number of investigators have examined the effects of opiate antagonists (naloxone and 
naltrexone) in individuals with autism, under the assumption that opioid hyperfunction may be an 
important mediator of autistic behavior. Most of these studies used naltrexone, and the effects on 
core symptoms of autism were modest, at best (Sandman, 1988; Herman et al., 1986; Campbell et 
al., 1989; Leboyer et al., 1992; Campbell et al., 1993). However, some studies showed a reduction 
in self-injurious behavior. The inconsistent benefit (varying from patient to patient) of opiate 
antagonists for self-injurious behavior is worth considering even if there is no benefit for core 
autistic symptoms. Self injury resistant to behavioral treatment is such a severe problem when it 
occurs that any treatment that can assist in its management on a case-by-case basis must be 
regarded as an asset. One serendipitous finding in the studies that looked for an effect of naltrexone 
on autism was a fairly consistent effect in reducing symptoms of hyperactivity and impulsive 
behavior (Aman & Langworthy, 2000). If confirmed and found to be safe, this could be an important 
use of naltrexone in this very vulnerable population. 
 
 
8. Cortisol 
Cortisol is a glucocorticoid that is released by the adrenal cortex in response to stress. Its 
secretion is controlled by the hormone adrenocorticotropin (ACTH), which is released from the 
pituitary. ACTH release, in turn, is under the control of corticotropin-releasing factor (CRF) which 
is produced in the hypothalamus. Normally, cortisol limits its own release via a feedback loop, by 
suppressing the release of CRF and ACTH. Abnormalities in this feedback mechanism have been 
studied extensively in depression, using the dexamethasone suppression test (DST; Gwirtsman, 
Gerner, & Sternbach, 1982). 
Cortisol functioning in autism has been evaluated to assess the theory that some of the 
related behavioral disturbances could be due to a chronic heightened level of activation and 
hyperarousal, which might result in elevated levels of this stress hormone. Eleven studies 
(summarized in Table 6) have examined basal levels of cortisol, ACTH, or response to 
dexamethasone. Five studies using blood measurements of cortisol or ACTH found no differences 
between autistic and control subjects, which suggests that baseline levels of cortisol functioning 
are not greatly altered in autism. The largest study, involving 48 individuals with autism, did find 
significantly elevated levels of ACTH and normal levels of cortisol (Tordjman et al., 1997). It has 
been established that plasma ACTH is a good marker for acute stress. Cortisol, on the other hand, 
has a longer half-life and has a significantly longer latency to respond to stress, providing a better 
measure for basal stress levels (Tordjman et al., 1997). Therefore, rather than providing evidence 
for a chronic hyperarousal state, these results suggest that individuals with autism exhibit a 
heightened stress response to experimental procedures, such as the drawing of blood. These results 
are in agreement with observations of elevated blood NE and BE discussed previously. 
It is interesting, however, that the two studies involving DST have shown that some 
individuals with autism do not display normal suppression of cortisol. This finding may provide 
further evidence for abnormalities in serotonergic or noradrenergic functioning, as workers have 
suggested that these neurotransmitters may have a regulatory effect on ACTH and CRF release 
(Butterweck, Winterhoff, & Herkenham, 2001; Maccari et al., 1992; Stokes & Sikes, 1987). 
Further research is needed to clarify these findings. 
8.1. Clinical/treatment implications 
Other areas of medicine make use of agents that mimic, suppress, or regulate the HPA axis. 
Unfortunately, such strategies carry considerable risk, so the benefits would have to be considerable 
to justify this as a therapeutic approach. We were unable to find therapeutic trials of medications 
that affect cortisol release in subjects with autism. 
9. Amino acid neurotransmitters: glutamate and GABA 
Glutamate and gamma-aminobutyric acid (GABA) are the two transmitter substances that 
are linked to widespread synaptic communication in the CNS. Glutamate is the principal 
excitatory transmitter substance in the brain and spinal cord, whereas GABA is responsible for 
most of the inhibitory communication in the brain (Carlson, 2001; Kandel 
 
 
et al., 1995). Glycine is the principle inhibitory transmitter in the spinal cord and lower brain stem. 
These substances are widely produced in the central nervous system by the cells’ metabolic 
processes, and their effects are very widespread; there are few, if any, areas in the brain that do not 
receive input from glutamate and GABA (Carlson, 2001). Research in these two neurotransmitters 
has been tightly-linked, as GABA is converted from glutamate by the enzyme glutamic acid 
decarboxylase (GAD). GAD is the rate-limiting step of the synthesis of GABA. 
Despite their pervasiveness in brain activity and function, these amino acid 
neurotransmitters have received very little attention in the study of autism. However, researchers 
have begun to investigate whether or not either substance could play a role in autism’s expression. 
This is, in some respects, a different approach from previous neurochemical investigations. Rather 
than trying to identify multiple abnormalities in relatively independent systems, the study of 
glutamate and GABA posits that autism may be the result of a single dysfunction that in turn has 
broad repercussions (Hussman, 2001). 
Most theories regarding these amino acid neurotransmitters in autism suggest that the 
GABAergic system is suppressed, resulting in excessive stimulation of the glutamate system. This 
can be attributed to several findings. First, researchers have found abnormalities of cellular 
development in the limbic system and cerebellum postmortem (Bauman & Kemper, 1994; 
Raymond, Bauman, & Kemper, 1996). These areas are normally enriched with glutamate 
receptors. Researchers have theorized that overactivity of glutamate could result in 
‘‘excitotoxicity’’ which could cause aberrant neuronal development (Bittigau & Ikonomidou, 
1997). In addition, glutamate activity peaks during the second year of life (Kornhuber, 
Mack-Burhardt, Konradi, Fritze, & Riderer, 1989), which is a time when symptoms of autism often 
emerge. If this system is hyperfunctional, it is possible that neuronal growth and connectivity are 
damaged during critical periods of development. Excessive glutamatergic stimulation is also 
associated with seizures, which are common among individuals with autism (Hussman, 2001). 
Recently, a group of researchers examined brain levels of GAD, the rate-limiting step in the 
synthesis of GABA, in five autistic and eight control subjects postmortem (Fatemi et al., 2002). They 
found that this enzyme was reduced by 48–61% in parietal and cerebellar areas of brains of 
individuals with autism when compared to controls. These differences were statistically 
significant, and provided some initial evidence for abnormalities in glutamate/GABA. 
At this point, it is unclear as to whether or not an imbalance in the glutamate and GABA 
neurotransmitters contributes to the etiology of autism. However, postmortem research in this area 
is intriguing, and further research is needed. 
9.1. Clinical/treatment implications 
Much is already known about both glutamate and GABA metabolism and 
neurotransmission in general that might be applied empirically case-by-case in autism. The classic 
GABAergic agents available, such as clonazepam and lorazepam, seem of relatively low risk other 
than addiction or sudden withdrawal. Another intriguing possibility, one that would require 
long-term research to establish benefit-risk ratio, would be preventive treatment with GABA 
agents when autism first manifests in toddlerhood to neutralize excess glutamate excitotoxicity and 
to prevent progression of the disorder. However, the existing trials are not cause for optimism. Two 
studies examining pharmacologic treatments that affect the glutaminergic system were located. 
One assessed the effects of lamotrigine, which is thought to modulate glutamate’s activity but 
which also weakly inhibits the serotonin 5HT3 receptor (Belsito, Law, Kirk, Landa, & 
Zimmerman, 2001). In a double-blind, placebo-controlled study, either lamotrigine or placebo was 
administered to twenty-eight children with autism, aged between 3 and 11 years, chosen for the 
presence of autism but no additional behavioral symptoms. Very little improvement in autism 
symptoms was noted with treatment with active drug. King et al. (2001) reported findings from a 
double-blind, placebo-controlled study of amantadine (an antagonist at the N-methyl-D-aspartate 
subtype of glutamate receptor but also with anticholinergic effects) in 39 subjects with autistic 
disorder. While significant improvements were noted on the clinician-rated scores for 
Hyperactivity and Inappropriate Speech subscales of the Aberrant Behavior Checklist (Aman, 
Singh, Stewart, & Field, 1985) during treatment with amantadine, no differences from placebo were 
noted for parent measures (Aberrant Behavior Checklist) and in clinician’s ratings of global 
improvement. 
Hollander, Dolgoff-Kasper, Cartwright, Rawitt, and Novotny (2001) openly treated 14 
patients (mostly children) with autism spectrum disorders with divalproex sodium (DVPX). DVPX 
inhibits catabolic enzymes of GABA, but it also blocks voltage-dependent sodium channels. The 
patients were described as having affective instability (e.g., were impulsive and aggressive). 
Retrospective analysis suggested that 10 patients (72%) showed improved behavior with DVPX. 
Marrosu, Marrosu, Rachel, and Biggio (1987) described a series of seven children with autism who 
received intramuscular injections of diazepam and saline. Six of the seven children showed 
hyperactivity and all exhibited aggression when medicated with diazepam. Such an adverse 
response should not be surprising. It has long been known that children often show ‘‘paradoxical’’ 
excitability when treated with anxiolytic/sedatives (Werry & Aman, 1999) and children with 
autism appear to be no exception. 
10. Discussion 
At first glance, the bulk of neurochemical research in autism has been inconclusive, 
contradictory, and somewhat disappointing. Most of these studies employed few subjects and 
included comparison groups that were not appropriate, making it difficult to draw clear-cut 
conclusions. However, there appear to be some areas that may prove fruitful for future researchers. 
Clearly, serotonin remains the most promising area for future neurochemical research. With the 
development of sophisticated imaging and genetic techniques, researchers are beginning to 
delineate the potential abnormalities in central serotonergic functioning, such as focal regions of 
abnormal 5-HT synthesis and possible genetic differences in 5-HT transport. These preliminary 
results are intriguing and are in need of further study and replication. 
Recent work in neuropeptide functioning has suggested that oxytocin may also play a role 
in the pathogenesis of the disorder. This area of research is in its infancy, and further study is 
needed; particularly, it would be useful to get more direct central assessments of oxytocin via 
measurement of CSF. In addition, studies using positron-emission tomography to investigate 
central OT receptor distribution may also help elucidate the role of oxytocin in autism (Modahl et 
al., 1998). 
The place of neurotransmitters in early brain development (e.g., serotonin, acetylcholine, 
and glutamate) may prove to be a particularly important area of study. If certain systems are 
disrupted early in the development of the brain, it is possible that early pharmacological 
intervention could possibly help to treat and maybe even prevent some of the devastating features of 
autistic disorder. Theoretically, work in genetics may be able to identify these neurochemical 
abnormalities at birth, which may help to direct infants who are at risk for autism into the 
appropriate medical treatment. This would represent a completely new approach to the 
pharmacological management of autism. 
Review of the other neurochemical systems in autism was not as compelling. The evidence 
for DA’s role in autism was not convincing; however, there are discrepancies among the studies of 
central DA turnover, so further replication may be warranted. The studies of noradrenergic 
functioning have not provided any evidence for a clear role in autism’s pathogenesis, and it is 
unlikely that further investigation would prove otherwise. Studies of opioid functioning in autism 
have not produced much of clinical relevance thus far. Studies of baseline levels of cortisol have 
not shown any consistent abnormalities, though a high rate of non-suppression after 
dexamethasone warrants further pursuit. 
Upon review of this body of work, several methodological issues need to be addressed by 
future researchers. First, it is critical that future studies carefully assess and categorize research 
subjects by strict diagnostic and subject criteria for autism. Perusal of Tables 1–6 reveals that 
everything from ‘‘clinical impression’’ through to rigorous structured interview has been used in the 
past, but entry has relied on informal methods of classification in the past. Future research needs to 
go beyond the sole reliance on diagnostic methods such as the DSM-IV and the ADI-R in 
classifying subjects. Though these tools may be able to diagnose an individual with autistic 
disorder, there are inconsistent symptom profiles across individuals who meet these criteria. For 
example, individuals may be severely or mildly impaired, and may exhibit comorbid behavioral 
disturbances such as hyperactivity, aggression, or anxiety – such subject factors may likely reflect 
neurochemical function. Furthermore, recent research has also established that factors such as 
pubertal status and race can have significant effects on biochemical measurements. These 
characteristics must also be accounted for in control groups. Researchers need to control for these 
subject variables, and in doing so, they will be able to delineate what is unique to the 
pathophysiology of autism, and possibly reveal subcategories within the disorder that may guide 
future pharmacotherapy. 
Second, much of the neurochemical research in the past 35 years or so has focused on 
peripheral measures of neurochemical systems; this has limited what conclusions could be made 
about central functioning. However, recent advances in the basic neurosciences (such as PET, genetic 
techniques, and more sensitive assay methods) have opened the way to more relevant and 
informative assessments of central functioning. Thus, in time, the greatest challenge to meaningful 
neurochemical investigation in autism may well be the issues of clinical assessment discussed above 
(rather than limitations in neurobiological assessment). 
Third, looking for abnormalities in only one neurochemical system may be akin to 
searching for the ‘‘Holy Grail’’. For example, it is not clear why the atypical antipsychotics are often 
helpful in managing problem behaviors in autism. In this case, it could be that there is a dynamic 
balance between serotonergic and dopaminergic systems, and that this varies between patients, as 
well as between drugs. For example, serotonin is also known to have a regulatory action on 
dopamine levels. This idea of dynamic interaction might also be applied to other 
neurotransmitters, neuropeptides, and so forth. Thus, it may be more fruitful to look for a pattern of 
imbalance between candidate neurotransmitters than for simple elevations and deficiencies. 
Fourth, it is clear that the various subspecialties within the biological bases of behavior must 
continue (and increase) their collaborative efforts. The disciplines of neurochemistry, 
neuroanatomy, psychopharmacology, and genetics should work in concert to help uncover the 
biological bases of this disorder. It is becoming clear that autism may involve a cascade of complex 
gene-environmental interactions, and the study of neurochemistry in isolation may not be sufficient. 
This includes approaching the study of autism from a developmental perspective, investigating how 
early neuronal growth and differentiation could be aberrant or interrupted in individuals with the 
disorder. Recent advances in pharmacogenomics may prove to be a fruitful area of research, as may 
the continued postmortem studies of receptor distribution and neurochemistry. Bringing together 
experts of these respective areas to work in collaboration with one another is an exciting 
development that will hopefully lead to better treatments, if not a cure or prevention for this 
debilitating disorder. 
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